Most research on the relationship between neuroendocrine markers and psychotherapies has focused on major depression and depressive symptoms, which often co-occur with BPD (Paris, 2018), and a correlation between low OXT plasma levels and diminished symptom improvement after a cognitive behavioral treatment program was observed (Jobst et al., 2018). The gene discussed is OXT; the disease is major depressive disorder.